Analyst Price Targets — HBIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 11:08 am | — | New Street | $6.00 | $4.94 | StreetInsider | Harvard Bioscience Inc. (HBIO) PT Lowered to $0.60 at Benchmark After Q4 Results |
| August 8, 2024 3:09 pm | Paul Knight | KeyBanc | $70.00 | $31.20 | StreetInsider | KeyBanc Reiterates Overweight Rating on Harvard Bioscience Inc. (HBIO) |
Latest News for HBIO
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026.
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in the following upcoming investor events.
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HBIO.
U.S. House Trading
No House trades found for HBIO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.